By Chris Wack
Context Therapeutics Inc. shares were up 15%, to 90 cents, on Monday after the Philadelphia biotechnology company said that it is collaborating with Lonza to make CTIM-76, its Claudin 6 and CD3 T-cell engaging bispecific antibody targeting CLDN6 positive tumors.
The stock hit its 52-week low of 60 cents a share on Dec. 15 and is down 23% over the past three months.
The companies said that under the terms of the agreement, Swiss-based pharmaceutical and biotechnology company Lonza would provide a manufacturability assessment, gene and cell-line construction, and process development for CTIM-76.
CTIM-76's drug substance would be made at Lonza's Slough, England, site, while its drug product would be made at the Stein and Visp sites in Switzerland, the companies said.
Context Therapeutics said the collaboration is relying on Lonza's expertise in developing and manufacturing complex proteins, as well as its extensive regulatory competence and manufacturing network.
Write to Chris Wack at chris.wack@wsj.com
Bagikan Berita Ini
0 Response to "Context Therapeutics Shares Rise 15% After Lonza Manufacturing Pact - MarketWatch"
Post a Comment